APOGEE THERAPEUTICS INC (APGE) — insider trading
Health Care · NASDAQ
APOGEE THERAPEUTICS INC (APGE) has 91 reported SEC Form 4 insider transactions in our data, including 23 open-market sales among the most recent 91 (latest 2026-09-03).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-03 | McKenna Mark C. | Director | Disposition to the issuer (derivative) | 7,657 | — | — | Form 4 |
| 2026-09-03 | McKenna Mark C. | Director | Disposition to the issuer (derivative) | 14,461 | — | — | Form 4 |
| 2026-09-03 | McKenna Mark C. | Director | Disposition to the issuer (derivative) | 10,370 | — | — | Form 4 |
| 2026-09-03 | McKenna Mark C. | Director | Disposition to the issuer (derivative) | 150,000 | — | — | Form 4 |
| 2026-09-03 | McKenna Mark C. | Director | Disposition to the issuer | 20,000 | — | — | Form 4 |
| 2026-09-03 | JONES WILLIAM A JR | Director | Disposition to the issuer (derivative) | 7,657 | — | — | Form 4 |
| 2026-09-03 | JONES WILLIAM A JR | Director | Disposition to the issuer (derivative) | 14,461 | — | — | Form 4 |
| 2026-09-03 | JONES WILLIAM A JR | Director | Disposition to the issuer (derivative) | 10,370 | — | — | Form 4 |
| 2026-09-03 | JONES WILLIAM A JR | Director | Disposition to the issuer | 34,824 | — | — | Form 4 |
| 2026-09-03 | Dambkowski Carl | Officer (Chief Medical Officer) | Disposition to the issuer (derivative) | 83,690 | — | — | Form 4 |
| 2026-09-03 | Dambkowski Carl | Officer (Chief Medical Officer) | Disposition to the issuer (derivative) | 124,962 | — | — | Form 4 |
| 2026-09-03 | Dambkowski Carl | Officer (Chief Medical Officer) | Disposition to the issuer (derivative) | 110,665 | — | — | Form 4 |
| 2026-09-03 | Dambkowski Carl | Officer (Chief Medical Officer) | Disposition to the issuer | 167,123 | — | — | Form 4 |
| 2026-09-03 | Fox Jennifer A. | Director | Disposition to the issuer (derivative) | 7,657 | — | — | Form 4 |
| 2026-09-03 | Fox Jennifer A. | Director | Disposition to the issuer (derivative) | 14,461 | — | — | Form 4 |
| 2026-09-03 | Fox Jennifer A. | Director | Disposition to the issuer (derivative) | 10,370 | — | — | Form 4 |
| 2026-09-03 | Fox Jennifer A. | Director | Disposition to the issuer | 34,824 | — | — | Form 4 |
| 2026-09-03 | Henderson Jane | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 83,690 | — | — | Form 4 |
| 2026-09-03 | Henderson Jane | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 124,962 | — | — | Form 4 |
| 2026-09-03 | Henderson Jane | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 175,345 | — | — | Form 4 |
| 2026-09-03 | Henderson Jane | Officer (Chief Financial Officer) | Disposition to the issuer | 158,371 | — | — | Form 4 |
| 2026-09-03 | Bollinger Lisa | Director | Disposition to the issuer (derivative) | 7,657 | — | — | Form 4 |
| 2026-09-03 | Bollinger Lisa | Director | Disposition to the issuer (derivative) | 14,461 | — | — | Form 4 |
| 2026-09-03 | Bollinger Lisa | Director | Disposition to the issuer (derivative) | 8,112 | — | — | Form 4 |
| 2026-09-03 | Bollinger Lisa | Director | Disposition to the issuer (derivative) | 18,550 | — | — | Form 4 |
| 2026-09-03 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Disposition to the issuer (derivative) | 253,016 | — | — | Form 4 |
| 2026-09-03 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Disposition to the issuer (derivative) | 357,036 | — | — | Form 4 |
| 2026-09-03 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Disposition to the issuer (derivative) | 387,012 | — | — | Form 4 |
| 2026-09-03 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Disposition to the issuer | 920,941 | — | — | Form 4 |
| 2026-09-03 | Shah Nimish P | Director | Disposition to the issuer (derivative) | 365,853 | — | — | Form 4 |
| 2026-09-03 | Shah Nimish P | Director | Disposition to the issuer (derivative) | 7,657 | — | — | Form 4 |
| 2026-09-03 | Shah Nimish P | Director | Disposition to the issuer (derivative) | 14,461 | — | — | Form 4 |
| 2026-09-03 | Shah Nimish P | Director | Disposition to the issuer (derivative) | 10,370 | — | — | Form 4 |
| 2026-09-03 | Shah Nimish P | Director | Disposition to the issuer (derivative) | 47,758 | — | — | Form 4 |
| 2026-09-03 | Shah Nimish P | Director | Disposition to the issuer (derivative) | 6,743,321 | $135.11 | $911.09M | Form 4 |
| 2026-09-03 | Shah Nimish P | Director | Disposition to the issuer | 1,750,000 | $135.11 | $236.44M | Form 4 |
| 2026-09-03 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Disposition to the issuer (derivative) | 7,657 | — | — | Form 4 |
| 2026-09-03 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Disposition to the issuer (derivative) | 14,461 | — | — | Form 4 |
| 2026-09-03 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Disposition to the issuer (derivative) | 10,370 | — | — | Form 4 |
| 2026-09-03 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Disposition to the issuer (derivative) | 47,758 | — | — | Form 4 |
| 2026-09-03 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Disposition to the issuer (derivative) | 6,743,321 | — | — | Form 4 |
| 2026-09-03 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Disposition to the issuer | 51,166 | — | — | Form 4 |
| 2026-09-03 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Disposition to the issuer | 51,166 | — | — | Form 4 |
| 2026-09-03 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Disposition to the issuer | 340,855 | — | — | Form 4 |
| 2026-09-02 | Dambkowski Carl | Officer (Chief Medical Officer) | Disposition to the issuer | 1,375 | $135.06 | $185.7K | Form 4 |
| 2026-08-07 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Option exercise / conversion (derivative) | 10,370 | — | $0 | Form 4 |
| 2026-08-07 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Option exercise / conversion (derivative) | 31,838 | — | $0 | Form 4 |
| 2026-08-07 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Option exercise / conversion | 10,370 | $43.85 | $454.7K | Form 4 |
| 2026-08-07 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Option exercise / conversion | 31,838 | $17.00 | $541.2K | Form 4 |
| 2026-08-05 | Dambkowski Carl | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 4,125 | — | $0 | Form 4 |
| 2026-08-05 | Dambkowski Carl | Officer (Chief Medical Officer) | Open-market sale | 5,500 | $134.17 | $737.9K | Form 4 |
| 2026-08-05 | Dambkowski Carl | Officer (Chief Medical Officer) | Option exercise / conversion | 4,125 | $22.86 | $94.3K | Form 4 |
| 2026-07-24 | Henderson Jane | Officer (Chief Financial Officer) | Bona fide gift | 15,000 | — | $0 | Form 4 |
| 2026-07-14 | Dambkowski Carl | Officer (Chief Medical Officer) | Bona fide gift | 8,000 | — | $0 | Form 4 |
| 2026-07-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Bona fide gift | 75,046 | — | $0 | Form 4 |
| 2026-07-08 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 20,000 | $133.63 | $2.67M | Form 4 |
| 2026-07-01 | Dambkowski Carl | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 4,125 | — | $0 | Form 4 |
| 2026-07-01 | Dambkowski Carl | Officer (Chief Medical Officer) | Open-market sale | 5,500 | $132.74 | $730.1K | Form 4 |
| 2026-07-01 | Dambkowski Carl | Officer (Chief Medical Officer) | Option exercise / conversion | 4,125 | $22.86 | $94.3K | Form 4 |
| 2026-06-22 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 80,000 | $132.54 | $10.60M | Form 4 |
| 2026-06-22 | Dambkowski Carl | Officer (Chief Medical Officer) | Open-market sale | 26,400 | $132.60 | $3.50M | Form 4 |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 614 | $86.89 | $53.4K | Form 4 |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 2,305 | $86.27 | $198.9K | Form 4 |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 1,577 | $85.19 | $134.3K | Form 4 |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 1,080 | $84.18 | $90.9K | Form 4 |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 7,654 | $82.78 | $633.6K | Form 4 |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 6,770 | $82.21 | $556.6K | Form 4 |
| 2026-06-09 | Bollinger Lisa | Director | Grant / award / vesting (derivative) | 7,657 | — | $0 | Form 4 |
| 2026-06-09 | Fox Jennifer A. | Director | Grant / award / vesting (derivative) | 7,657 | — | $0 | Form 4 |
| 2026-06-09 | JONES WILLIAM A JR | Director | Grant / award / vesting (derivative) | 7,657 | — | $0 | Form 4 |
| 2026-06-09 | McKenna Mark C. | Director | Grant / award / vesting (derivative) | 7,657 | — | $0 | Form 4 |
| 2026-06-09 | Shah Nimish P | Director | Grant / award / vesting (derivative) | 7,657 | — | $0 | Form 4 |
| 2026-06-09 | Fairmount Funds Management LLC; Kiselak Tomas | Director | Grant / award / vesting (derivative) | 7,657 | — | $0 | Form 4 |
| 2026-06-03 | Dambkowski Carl | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 4,125 | — | $0 | Form 4 |
| 2026-06-03 | Dambkowski Carl | Officer (Chief Medical Officer) | Open-market sale | 5,500 | $78.71 | $432.9K | Form 4 |
| 2026-06-03 | Dambkowski Carl | Officer (Chief Medical Officer) | Option exercise / conversion | 4,125 | $22.86 | $94.3K | Form 4 |
| 2026-05-13 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 1,341 | $82.58 | $110.7K | Form 4 |
| 2026-05-13 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 18,659 | $82.05 | $1.53M | Form 4 |
| 2026-05-06 | Dambkowski Carl | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 4,125 | — | $0 | Form 4 |
| 2026-05-06 | Dambkowski Carl | Officer (Chief Medical Officer) | Open-market sale | 1,800 | $84.60 | $152.3K | Form 4 |
| 2026-05-06 | Dambkowski Carl | Officer (Chief Medical Officer) | Open-market sale | 3,700 | $83.92 | $310.5K | Form 4 |
| 2026-05-06 | Dambkowski Carl | Officer (Chief Medical Officer) | Option exercise / conversion | 4,125 | $22.86 | $94.3K | Form 4 |
| 2026-05-01 | Henderson Jane | Officer (Chief Financial Officer) | Open-market sale | 289 | $83.16 | $24.0K | Form 4 |
| 2026-05-01 | Henderson Jane | Officer (Chief Financial Officer) | Open-market sale | 900 | $82.60 | $74.3K | Form 4 |
| 2026-05-01 | Henderson Jane | Officer (Chief Financial Officer) | Open-market sale | 811 | $81.02 | $65.7K | Form 4 |
| 2026-04-16 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-04-16 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 3,000 | $22.86 | $68.6K | Form 4 |
| 2026-04-16 | Henderson Jane | Officer (Chief Financial Officer) | Open-market sale | 2,000 | $90.00 | $180.0K | Form 4 |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 200 | $85.00 | $17.0K | Form 4 |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 2,000 | $83.26 | $166.5K | Form 4 |
| 2026-04-08 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 17,800 | $82.48 | $1.47M | Form 4 |
Ask the chat about APGE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: APOGEE THERAPEUTICS INC (APGE).
Last updated 2026-09-03 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.